ImmunoGen. has filed a patent for therapeutic combinations of immunoconjugates targeting CD123 with BCL-2 inhibitors and hypomethylating agents to treat hematological malignancies effectively with reduced toxicity. The patent also covers methods for treating minimal residual disease using immunoconjugates. GlobalData’s report on ImmunoGen gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights ImmunoGen Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on ImmunoGen, Nanoparticle drug conjugates was a key innovation area identified from patents. ImmunoGen's grant share as of January 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.

Combination therapy for hematological malignancies using immunoconjugates

Source: United States Patent and Trademark Office (USPTO). Credit: ImmunoGen Inc

A recently filed patent (Publication Number: US20240033371A1) outlines methods for treating hematologic malignancies in subjects by administering immunoconjugates that bind to CD123 and either venetoclax or azacitidine. The immunoconjugates consist of an antibody or antigen-binding fragment linked to a cytotoxin, with specific amino acid sequences detailed for the heavy and light chain variable regions. The cytotoxin used is a DNA-alkylating agent, and the administration of these immunoconjugates is proposed as a front-line therapy for hematologic malignancies such as acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Furthermore, the patent describes the administration of azacitidine in conjunction with the immunoconjugates, along with specific dosing regimens and cycles for the treatment. The methods outlined in the patent are tailored for subjects with hematologic malignancies expressing CD123 and are deemed suitable for those with an absolute neutrophil count above a certain threshold. The patent also addresses the treatment of unfit AML and BPDCN cases, emphasizing the potential of these immunoconjugates in managing these specific types of hematologic malignancies. Overall, the patent presents a detailed approach to utilizing immunoconjugates targeting CD123 in combination with venetoclax or azacitidine for the treatment of various hematologic malignancies, offering a novel therapeutic strategy in the field.

To know more about GlobalData’s detailed insights on ImmunoGen, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies